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Purpose: Identification of stage-specific prognostic/predictive biomarkers in papillary thyroid 21 
carcinoma (PTC) could lead to its more efficient clinical management. The main objective of this 22 
study was to characterize the stage-specific deregulation in genes and miRNAs expression in 23 
PTC to identify potential prognostic biomarkers. 24 
Methods: 495 RNASeq and 499 miRNASeq PTC samples (stage I-IV) as well as, respectively, 25 
56 and 57 normal samples were retrieved from The Cancer Genome Atlas (TCGA). Differential 26 
expression analysis was performed using DESeq2 to identify deregulation of genes and miRNAs 27 
between sequential stages. To identify the minority of patients who progress to higher stages, we 28 
performed clustering analysis on stage I RNASeq data. An independent PTC RNASeq data set 29 
(BioProject accession PRJEB11591) was also used for the validation of the results. 30 
Results: LTF and PLA2R1 were identified as two promising biomarkers down-regulated in a 31 
subgroup of stage I (both in TCGA and in the validation data set) and in the majority of stage IV 32 
of PTC (in TCGA data set). hsa-miR-205, hsa-miR-509-2, hsa-miR-514-1 and hsa-miR-514-2 33 
were also detected as up-regulated miRNAs in both PTC patients with stage I and stage III. 34 
Hierarchical clustering of stage I samples showed substantial heterogeneity in the expression 35 
pattern of PTC indicating the necessity of categorizing stage I patients based on the expressional 36 
alterations of specific biomarkers. 37 
Conclusion: stage I PTC patients showed large amount of expressional heterogeneity. Therefore 38 
risk stratification based on the expressional alterations of candidate biomarkers could be an 39 
important step toward personalized management of these patients. 40 
 41 








































































The incidence of thyroid cancer has been increased worldwide during the past decades. 47 
According to Globocan 2018, thyroid cancer is in ninth place for incidence with 567,000 cases 48 
worldwide. It is 3 times more prevalent in women with the incidence rate of 10.2 per 100,000 49 
[1]. Four major types of thyroid cancer, including Papillary (PTC), Follicular (FTC), Medullary 50 
(MTC) and Anaplastic Thyroid Carcinoma (ATC) have already been characterized, among 51 
which PTC is the most frequent histotype, comprising 85-90 % of all thyroid cancer cases. 52 
Despite good prognosis, lymph node or distant metastasis is observed in approximately 10% of 53 
PTC patients. Although it is still controversial, it has been suggested that there are specific PTC 54 
subtypes related to the risk of locoregional recurrence or distant metastasis [2]. 55 
Thyroid cancer staging provides prognostic information related to disease surveillance, 56 
risk stratification and therapeutic strategies. Accurate initial staging requires detailed data 57 
obtained from preoperative work up, intra operative findings and postoperative follow-up. 58 
Moreover risk stratification based on clinical and pathology risk factors or molecular profiling 59 
can be efficiently used to guide follow-up management decisions. According to the American 60 
Joint Committee on Cancer (AJCC) TNM staging system, based on the size of tumor (T), spread 61 
to nearby lymph nodes (N), and metastasis to distant sites (M), four stages for thyroid cancer (I-62 
IV) can be specified. Moreover the staging system uses a combination of risk factors such as age 63 
at diagnosis, size of the primary tumor, specific tumor histology, direct extension of the tumor to 64 
the outside of thyroid gland, loco-regional metastases, and/or distant metastases to stratify 65 
patients into various risk categories with differing risks of death from thyroid cancer. PTC has 66 
already been subjected to the large-scale genetic characterization studies through which the 67 




































































indicated that activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-69 
kinase AKT (PI3K-AKT) pathways through gene fusions or somatic mutations could be 70 
considered as primary alterations in PTC[5]. Recently Tengs and colleagues, in a comprehensive 71 
transcriptomics study, characterized a signature of deregulated genes and lncRNAs associated 72 
with extra-thyroidal extension. They have also suggested several biomarkers with the potential 73 
use in the early detection of thyroid cancer [6] 74 
In the present study we aimed to investigate the transcriptomic alterations between 75 
different PTC stages at both RNA and miRNA levels to identify specific transcriptional 76 
alterations in different stage transitions. Moreover, since most PTC patients do not progress to 77 
the higher stages, we were interested to identify the subgroup of PTC patients in stage I with the 78 
potential to progress into the higher stages. Having this knowledge about different PTC high-risk 79 
subgroups could help to stratify patients based on the molecular signatures of tumor. This may 80 
lead to the adoption of a personalized approach for treating PTC patients and to reduce the 81 





RNASeq and miRNASeq open access data on Thyroid Cancer Adenocarcinoma (PTC 87 
type) was retrieved from TCGA (http://portal.gdc.cancer.gov/) on Jul 2019. Tumor samples were 88 




































































(Table 1 and 2). All tumor samples were collected after surgery and patients were not subjected 90 
to any medical intervention including radioactive iodine ablation therapy. 91 
Differential Expression Analysis on RNASeq and miRNASeq data 92 
495 Illumina Genome Analyzer RNASeq raw counts (htseq-count) files of PTC in which 93 
the expression value of 60,483 transcripts had been measured, and 499 Illumina HighSeq raw 94 
counts covering 1,046 miRNAs, beside respectively 56 and 57 RNASeq and miRNASeq htseq-95 
count files of normal thyroid tissues were included in this study . Figure 1 shows the overall 96 
work flow of this study. Normalization steps and differential expression analysis between 97 
different stages, including “normal to stage I”, “stage I to II”, “stage II to III” and “stage III to 98 
IV” was performed separately using DeSeq2 package [7] in R 3.5.0. Transcripts and miRNAs 99 
with raw counts less than 10 were removed from all samples before normalization by DeSeq2. 100 
The list of the resulted differential expressed genes (DEGs) and miRNAs was then filtered for ≤ 101 
0.05 adjusted p-value and |log2 FC | ≥ 1. 102 
In order to validate the final results of our RNASeq analysis, we also analyzed another 103 
independent PTC RNASeq data set (bio project PRJEB11591) which was the only available data 104 
set including 77 PTC (49 stage I, 18 stage III and 2 stage IV ) beside 31 adjacent normal tissue 105 
samples. Trimming of paired end Fastq files was performed using Trimmomatic algorithm. 106 
Trimmed Fastq files were then mapped on human genome (homo sapiens) (b37): hg19 using 107 
BWA algorithm. The resulted bam files were then introduced in to htseq-count algorithm to 108 
produce count files for each sample. DeSeq2 program was then used to get the list of DEGs 109 
between normal vs. stage I and also between stage I vs. the integration of stage III and stage IV 110 




































































samples. Due to the same reason, differential expression analysis could not be carried out 112 
between stage III and stage IV. 113 
Contrasting and comparing deregulated genes and miRNAs across individual tumor stages 114 
In order to identify differences and similarities in the expression patterns of deregulated 115 
genes and miRNAs between different stages (including comparison of changes in direction, i.e., 116 
up to down-regulated, or down to up-regulated), the lists of the resulting differentially expressed 117 
genes and miRNAs were contrasted and compared between the results of the sequential stage 118 
comparisons.  119 
To identify interactions between deregulated miRNAs and their corresponding targets, 120 
the lists of deregulated miRNAs in four group studies were separately introduced into 121 
miRDB.V6 (http://mirdb.org) and their corresponding target genes were identified. These target 122 
genes were then searched in the list of deregulated genes with the opposite pattern of expression 123 
(for example target genes of down-regulated miRNAs in each group were searched in the list of 124 
up-regulated genes in that group). 125 
“Stage I” sample clustering of RNASeq and miRNASeq data 126 
We clustered all genes in “stage I” samples (278 RNASeq and 282 miRNASeq data sets) 127 
normalized htseq-count files,  using hierarchical clustering and applying “Euclidean distance” 128 
measure in GENE-E program(gene-e@broadinstitute.org).Visually separated clusters of patients 129 
with distances ≤ 0.4 were then identified. The expressional changes of each cluster of stage I 130 
tumor samples were compared with normal samples and the lists of deregulated genes and 131 




































































up-regulated genes and miRNAs in each cluster were compared with the lists of deregulated 133 
genes in different stage transitions (from normal to stage IV). 134 
A similar approach was used for the clustering of 49 stage I samples of the validation data. 135 
Gene enrichment analysis of identified deregulated genes 136 
To find deregulated pathways in each stage comparisons we performed pathway 137 
enrichment using Enrichr [8] and pathways with Benjamini-Hochberg adjusted p-value ≤ 0.05 138 
was reported. 139 
 140 
Results 141 
mRNAs and miRNAs deregulations 142 
The list of deregulated genes and miRNAs in different sequential stage progressions are 143 
respectively represented in Table 3-4 and Table 5. Deregulated genes and miRNAs were ranked 144 
based on their log2 FC of expression values. The results of the RNASeq validation study (normal 145 
to stage I and stage I to the integration of stage III-IV) showed the statistical significant results 146 
(adjusted p-value ≤ 0.05) for only normal to stage I comparison. 147 
mRNA 148 
Figure 2 and 3 show KEGG signaling pathways identified for up and down-regulated 149 
genes, respectively. Simultaneous down-regulation of RAC2, VAV1 and DOCK2 genes was 150 
observed in stage I to II progression. These proteins are involved in leukocyte transendothelial 151 




































































I to II) that are present at the leukocyte membrane and involved in leukocyte binding to the 153 
endothelial membrane which in turn leads to the direct activation of VAV1 and indirect 154 
activation of Rac2. Concerted up-regulation of several extra cellular matrix (ECM) proteins, 155 
including THBS1, THBS2, COL6A3, SPP1, TNC, FN1, LAMB3 and COL1A2, along with 156 
ITGA11 (an ECM associated receptor) was observed in stage II to III transition. The up-157 
regulation of these proteins results in the considerable activation of PI3K-AKT pathway and 158 
therefore leads to the continuous cell proliferation [9]. Moreover the activation of TGF-beta 159 
signaling pathway which contributes to the epithelial-mesenchimal transition (EMT), has 160 
previously been indicated following the up-regulation of THBS1( up-regulated in stage II to III 161 
progression) [11]. 162 
The up-regulation of three MHC class II members, including HLA-DOA, HLA-DQA1 163 
and HLA-DRB1, was detected in stage II to III progression. The higher frequency of HLA-164 
DRB1 in PTC patients compared to controls has been already demonstrated [12]. Similar results 165 
were demonstrated by JO and colleagues who also indicated that the expression of MHC class II 166 
antigens (HLA-DQ and HLA-DR) is inversely correlated with the recurrence of PTC [13]. 167 
Comparing the list of up and down-regulated genes between pairs of continuous stages 168 
resulted in the identification of 3 down-regulated genes that were also detected as down-169 
regulated in higher stages. These include FBLN1, identified as down-regulated in the “normal to 170 
stage I”, and also in “stage I to II” progression. Similarly, LTF and PLA2R1 were identified as 171 
down-regulated in both “normal to stage I” and “stage III to IV” progressions. No common up-172 




































































In order to identify any inversion in gene expression pattern between two continuous 174 
stages (e.g. down/up-regulated in “normal to stage I”, but up/down-regulated in stage I to II), the 175 
list of DEGs between each pair of continuous stages was compared with its immediate next 176 
stages pair. This led to the identification of a few genes with inverse pattern of expression (Table 177 
6). Notably, 28 down-regulated genes in “stage I to II” progression were also identified as up-178 
regulated in “stage II to III”. The corresponding KEGG signaling pathways for these 28 genes 179 
has been shown in Figure 4. Several numbers of these genes have a direct or indirect role in the 180 
activation of apoptosis. These include HLA-DOA, HLA-DQA, BIRC3, COL1A1 and IL2RG. 181 
Down-regulation of these genes in stage II is expected in the primary stages of tumor 182 
development. However their over-expression, which leads to the increase of apoptotic activity, 183 
has also been previously confirmed in some malignancies including breast, endometrial and 184 
thyroid cancers [14]. This increase in the apoptotic activity has previously been shown to be due 185 
to the presence of hypoxic conditions in the core regions of solid tumors and indicating the large 186 
area occupied by tumor cells [15]. Similarly, changing the pattern of expression from down to 187 
up-regulated was observed for RAC2 which along with DOCK2 and VAV1 (identified as down-188 
regulated in stage I to II progression), are associated with the regulation of actin cytoskeleton, 189 
production of reactive oxygen species (ROS) and metastasis [9]. 190 
miRNA 191 
There is large discrepancy among the results of studies on miRNA expression in thyroid 192 
cancer [20]. However the deregulation of several identified miRNAs in this study has previously 193 
been well confirmed in PTC (bold fonts in Table 5). Among previously reported deregulated 194 
miRNAs, the up-regulation of hsa-miR-146b and hsa-miR-222 and the down-regulation of hsa-195 




































































continuity in the pattern of expressional alteration (for example down regulation of the same 197 
gene in two sequential stage transitions), the lists of up and down-regulated miRNAs were 198 
compared between sequential stage transitions. hsa-miR-205, hsa-miR-509-2, hsa-miR-514-1, 199 
and hsa-miR-514-2 were four miRNAs which their up-regulations was detected in both ”normal 200 
to stage I” and in “stage II to III” progressions. Similarly, hsa-miR-9-1 and hsa-miR-9-2 were 201 
identified as down-regulated in “normal to stage I” and “stage I to II” progressions. Moreover, 202 
inversion in the pattern of miRNAs expression between sequential stage was observed for hsa-203 
miR-1247, detected as down-regulated in “stage I to II”, and up-regulated in “stage II to III” 204 
progression.  205 
Comparing down and up-regulated miRNAs in each miRNAs clusters with the list of deregulated 206 
miRNAs obtained from stage comparisons was resulted in to the identification of hsa-miR-1247 207 
which its down-regulation was observed in cluster 4 of “stage I”, and also in “stage I to II” 208 
progression. However it was also detected as up-regulated in “stage II to III” progression. In 209 
addition, respectively the up and down-regulation of hsa-miR-34a and hsa-miR-486 in normal to 210 
stage I progression was detected. The results of searching for the targets of these two miRNAs 211 
among deregulated genes led to the identification of HSPA1B (down-regulated) and SFRP1 (up-212 
regulated) in normal to stage I progression. 213 
 214 
Results of stage I tumor sample clustering in TCGA and validation data set 215 
Clustering of stage I subjects revealed 6 distinct clusters for RNASeq, and 5 clusters for 216 
miRNASeq (Table 7) (Figures 5 and 6). Stage I RNAseq sample clustering revealed much more 217 




































































of 278 tumor samples, after removing outliers) of stage I RNASeq samples were subjected to 219 
more in-depth analyses. Comparing the lists of down and up-regulated genes in each “stage I” 220 
cluster (Supplementary table 1) with the lists of deregulated genes in higher stages led to the 221 
identification of few deregulated genes (Table 8).  222 
LTF which its down-regulation was also identified in “stage III to IV” progression was 223 
identified in cluster 3 of “stage I including 102 samples. Since we did not expect tumor 224 
progression to the highest stage (stage IV) for a large number of PTC patients, we further sub-225 
clustered these 102 samples in order to find a specific sub-cluster with the most contribution to 226 
the observed down-regulation of LTF. A total of 7 sub-clusters were identified in “cluster 3” of 227 
“stage I”. Running DeSeq2 to identify deregulated genes in each cluster, showed that in only one 228 
sub-cluster (containing 21 samples), LTF was significantly down-regulated (log2 FC =-3). This 229 
level of down-regulation (8 fold reduction in expression) appeared to have a significant influence 230 
on LTF average expression in the whole cluster 3 (Table 8).  231 
No deregulated genes were detected in “cluster 4” of stage I compared to the higher 232 
stages. Therefore it seems that patients in clusters “1, 2, 5 and 6” of stage I, as well as 21 patients 233 
in “cluster 3” (totally comprising 71 subjects out of 278 stage I tumor samples) which have 234 
shown further deregulation in higher stages, would probably be in the higher risk for tumor 235 
progression. No statistically significant difference between the potential high and low risk (71 vs. 236 
207) groups of stage I patients was detected based on their age, age of onset, race and sex. 237 
The changes in the expressional pattern of two identified genes i.e. LTF and PLA2R1 238 
was also checked in different stage I clusters’ of the validation data set. In total 3 clusters of 239 




































































expression of LTF and PLA2R1 showed mild down-regulation in C1 and C2, their significant 241 
down-regulation was observed in C3 which includes only 6 samples (log2 FC = -3.78 and -3.57 242 
for LTF and PLA2R1 respectively, equals to approximately 13.5 fold expressional reduction). 243 
This indicates almost similar percentage of stage I patients with significant down-regulation of 244 
LTF and PLA2R1 (for LTF, 21 out of 262 samples (8%) in TCGA data set and 6 out of 49 (12%) 245 
in the validation data set and for PLA2R1, 42 out of 262 samples (16%) in TCGA data set and 6 246 
out of 49 (12%) in the validation data set). 247 
Discussion 248 
Despite good prognosis of PTC, it has been indicated that a sub-group of PTC patients show an 249 
aggressive phenotype characterized by local recurrence and/or distant metastasis [18]. 250 
Characterizing DNA level molecular alterations of PTC including mutations and structural 251 
variations has already been the subject of several studies [2, 19]. Recently, a few transcriptomic 252 
investigations have also been conducted to generate a comprehensive view of PTC molecular 253 
alterations [6, 20]. Results of these studies have suggested several biomarkers that may have 254 
application in the early detection of PTC or as novel therapeutic targets. However no systematic 255 
study has been conducted to unravel the stage specific transcription alterations occurring in PTC. 256 
The identified stage-specific transcriptional alterations in our study can significantly improve our 257 
understanding about the gene expression signature of different PTC stages and suggests potential 258 
biomarkers which could potentially be implemented to classify subgroups of patients who might 259 
progress to the more advanced stages. 260 




































































The deregulation of a total of 12 genes in different sub-clusters of stage I were further 262 
identified in higher stages (Table 7). As we expected, for the majority of stage I PTC samples 263 
(207), no further deregulation was observed in the higher stages. 264 
LTF and PLA2R1 were two down-regulated tumor suppressors in “stage I” that 265 
interestingly, exhibited further down-regulation in “stage III to IV” progression. The association 266 
of down-regulation of LTF with the poor prognosis of PTC has recently been indicated [21].The 267 
role of PLA2R1 in the activation of signaling pathways related to apoptosis and senescence and 268 
its down-regulation in some cancers including thyroid, renal, mammary and leukemia has been 269 
also previously established [22]. As stated earlier, the significant down-regulation of LTF and 270 
PLA2R1 was also confirmed in respectively 12% and 16% of stage I samples of the validation 271 
data set. However as a result of the small number of stage IV samples (only 2 samples), we could 272 
not check their expressional changes in stage III to IV progression in the validation data set. 273 
Nevertheless it seems that these two genes can be considered as the potential biomarkers 274 
associated with the poor prognosis in PTC. 275 
TRIB3 and KIF5C are other two down-regulated genes in stage I which were also 276 
detected as down-regulated in stage II to III progression. TRIB3 is a tumor suppressor which its 277 
loss has been shown to lead to the enhanced phosphorylation of AKT and in turn to the 278 
hyperphosphorylation of FOXO3 which results to its inactivation [23]. There are contradictory 279 
reports about  KIF5C pattern of deregulation in thyroid cancer (both the down and up-regulation 280 
of KIF5C in thyroid tumors has already been reported) [24, 25]. 281 
There is still no report about the deregulation of SNX20 in thyroid cancer. However in a very 282 




































































and in circulating cell free DNA (cfDNA) of a follicular thyroid carcinoma patient with lung and 284 
bone metastasis [26]. 285 
The further up-regulation of all seven up-regulated genes in different sub-clusters of stage 286 
I were identified in stage II to III progression (Table 8). Among these, CST7 and FN1 were two 287 
genes that have previously been suggested as biomarkers associated with poor prognosis of PTC 288 
[6, 27]. Similarly the over-expression of TNFSF13B in tumor cells has been shown to be related 289 
to the poor prognosis in non small cell lung cancer [28].The up-regulation of SCEL in PTC has 290 
previously been demonstrated by Huang and colleagues [29]. The genetic polymorphism of 291 
IL1RN has been previously associated with the poor prognosis in cancer [30]. Moreover IL1RN 292 
has been already suggested as a biomarker involved in tumor differentiation of thyroid 293 
carcinoma [18]. 294 
Several studies has previously confirmed that the hypermethylation of Runx3 is in 295 
association with poor prognosis of thyroid cancer [8, 31, 32]. However we identified RUNX3 as 296 
an up-regulated gene in both a very small sub-cluster of “stage I” (including 3 samples) and also 297 
in stage “I to II” progression. Interestingly the results of a recent comprehensive meta-analysis 298 
conducted on three different cancers (including Breast, Colon and Lung), provide further 299 
interesting evidence about the direct relationships between the level of hypermethylation of 300 
genes and the levels of genes expression. They indicated that except for the genes that are lowly 301 
expressed in normal tissues, the hyper or hypomethylation of genes in cancer tissue does not 302 
necessarily result in respectively their down or up-regulation [33]. 303 
No significant difference was identified between the age, age of onset, race and sex of 304 




































































transcriptional biomarkers for classifying PTC patients and selecting the efficient personalized 306 
treatment. 307 
Prognostic miRNAs for PTC tumor progression 308 
As stated earlier, the results of miRNA expression studies vary significantly due to the 309 
several factors including the heterogeneity of tumor samples, the variations in sample size and in 310 
the quantitative method implemented for expression measurements. The problem becomes more 311 
complex considering the fact that there is a direct correlation between the deregulation of some 312 
miRNAs with some oncogenic mutations. For instance, the up-regulation of hsa-miR-146b, hsa-313 
miR-221, hsa-miR-222, hsa-miR-21-5p, hsa-miR-31-5p, hsa-miR-34a-5p, hsa-miR-181b-5p and 314 
hsa-miR-551b-3p have been confirmed in BRAF V600E samples [34]. 315 
In spite of the large number of analyzed tumor samples in the present study, due to the 316 
imbalance between the numbers of tumor vs. normal samples, the results of this study are not 317 
comparable to other studies performed on miRNA expression alterations in PTC. However as it 318 
is shown in Table 5, the deregulation of a considerable number of identified miRNAs have 319 
already been confirmed by several studies. As stated in the results section, the down-regulation 320 
of hsa-miR-205, hsa-miR-509-2, hsa-miR-514-1, and hsa-miR-514-2 were detected in both stage 321 
I and stage III and therefore after further confirmation they can be implemented as new 322 
predictors of tumor progression. There are contradictory reports about the expression pattern of 323 
hsa-miR-1247 (detected as down-regulated in stage I and up-regulated in stage III). Down-324 
regulation of hsa-miR-1247 has previously been reported in thyroid tumors with follicular 325 
pattern of growth [35]. Similarly the down-regulation of hsa-miR-1247 has been confirmed in 326 




































































regulation of this miRNA with lung metastasis has been shown in liver cancer. It has been 328 
indicated that tumor derived exosomal hsa-miR-1247 affects cancer associated fibroblasts and 329 
activates lung metastasis [37]. 330 
Expression measurements of other identified deregulated miRNAs with no previous 331 
reports on their association with PTC, in a large number of PTC patients, will reveal if they can 332 
be truly considered as the novel prognostic biomarkers in PTC. As stated in results section, 333 
searching for the targets of deregulated miRNAs among the list of deregulated mRNAs led to the 334 
identification of two regulatory interactions in normal to stage I progression between HSPA1B 335 
(down-regulated) - hsa-miR-34a (up-regulated) and between SFRP1 (up-regulated)-has-miR-486 336 
(down-regulated). HSPA1B is a negative modulator of cell proliferation, differentiation and 337 
inflammation and its prognostic value in detection of different subtypes of breast cancer has 338 
recently been demonstrated [38]. Tumor promoting function of SFRP1 through the modulation 339 
of Wnt signaling pathway have also previously indicated in several cancers [39].  The few 340 
number of identified regulatory interactions between  deregulated miRNAs and target genes, is 341 
however in accordance with studies demonstrating that the most alterations in mRNA expression 342 
are short term and independent of miRNAs [34]. 343 
We believe that the strength of this study lies in its stage-wise approach, which to the best of our 344 
knowledge, has not already been performed in PTC.  345 
 Moreover the large sample size used in this study increases the confidence of our results. The 346 
main limitations of this study include the small number of normal samples compared to the large 347 
number of tumor samples and also the lack of complete demographic data for the PTC patients 348 
included in this study. Recently the expression of candidate genes in liquid-based cytology 349 




































































suggested genes and miRNAs in this study can also be measured in the liquid-based cytology 351 
specimens of different stages of PTC and especially in indeterminate categories.  352 
 353 
Conclusion 354 
We found large amount of heterogeneity in the gene expressional pattern of stage I PTC patients. 355 
Stratifying these patients in to high and low risk subgroups could help us to select more 356 
personalized cancer management in these patients. Stage-specific biomarkers identified in stage I 357 
PTC patients could efficiently help to distinguish the majority of patients with low risk of cancer 358 
progression from those who might progress to higher stages in PTC. 359 
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 Figure legends: 473 
Figure 1: Overall work flow of the study. 474 
Figure 2: Down-regulated genes in PTC (blue) involved in signaling pathways (pink). 475 
Figure 3: Up-regulated genes in PTC (blue) involved in signaling pathways (green). 476 
Figure 4: Pathways (light blue) associated with deregulated genes (orange) with the altered 477 
pattern of expression in stage I to II and stage II to III progressions. 478 
Figure 5:  Clustering of stage I patients using GeneE program. 479 
Table legends: 480 
Table 1: Number of samples in stage I-IV as well as normal thyroid tissue samples. 481 
Table 2: Clinical information of samples (Stage I-V). 482 




































































Table 4: Down-regulated genes in PTC continuous stage progressions. 484 
Table 5:  Deregulated miRNAs in the different stage progressions. 485 
Table 6:  Lists of DEGs with the opposite pattern of expression between different stages. 486 
Table 7: Different clusters identified by hierarchical clustering in stage-I samples. 487 
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Stages  RNASeq miRNASeq
Normal 56 57
Stage I 278 282
Stage II 50 52
Stage III 112 112
Stage IV 55 53
Table1 Click here to access/download;Table;Table 1.xls
Stages Stage I Stage II Stage III Stage IV
Age (mean-stdev) 44.8-12.8 64.5-11.4 64.8-11.1 65.5-9.9
Age at onset (mean-stdev) 38.8-13 58-11.7 59.2-10.8 60.9-10.2
Sex (female-male)% 76.1-23.9 76.9-23.1 71.7-28.3 58.2-41.8
White% 64.9 59.6 76.2 60
Asian% 12.3 9.6 6.2 9.1
Black or african-american% 3.9 1.9 7 9.1
not-reported% 18.6 28.8 11.6 21.8
Table2 Click here to access/download;Table;Table 2.xls
normal to stage I stage I to II stage II to III 
SFRP1 (1.7) IGF2 (4.1) DCN (2.28)
ECM1 (1.36) PTGDS (1.2) ALOX5 (2.17)
CDH2 (1.07) CKMT2 (1.09) FBLN1 (2.12)
SUSD2 (1.06) SLC43A1 (1.04) GNLY (2.07)
ESM1 (1.04) COL1A1 (2.06)



























































































normal to stage I stage I to II stage II to III stage III to IV
NR4A3 (-1.38) GBP5 (-1.75) KIF5C (-1.62) IPCEF1 (-1.64)
APOD (-1.19) BIRC3 (-1.7) ECM1 (-1.35) DGKI (-1.41)
FOSB (-1.17) CYTIP (-1.68) TRIB3 (-1.25) PLA2R1 (-1.28)
FBLN1 (-1.17) TRBC2 (-1.65) ESM1 (-1.21) LTF (-1.18)
TCAP (-1.14) IL2RG (-1.65) HSPB7 (-1.2) TFCP2L1 (-1.1)
SMOC2 (-1.07) CD48 (-1.58) RNF157 (-1.11) MT1F (-1.07)
PLA2R1 (-1.06) C1S (-1.54) SLC43A1 (-1.1)
LTF (-1.05) PTPRC (-1.52) CKMT2 (-1.06)
HSPA1B (-1.05) FCMR (-1.5)
BMP2 (-1.02) IRF8 (-1.49)


























































normal to stage I (ups) Stage II to III (ups) normal to stage I (downs)
hsa-miR-146b (5.17*) hsa-mir-205 (2.41) hsa-mir-7-3 (-2.23)
hsa-miR-551b (4.46) hsa-mir-136 (1.49) hsa-mir-1179 (-1.95)
hsa-miR-221 (3.18) hsa-mir-154 (1.35) hsa-mir-144 (-1.84)
hsa-miR-187 (2.97) hsa-mir-382 (1.25) hsa-mir-873 (-1.82)
hsa-miR-222 (2.84) hsa-mir-1247 (1.18) hsa-mir-451 (-1.78)
hsa-miR-375 (2.73) hsa-mir-369 (1.17) hsa-mir-486 (-1.65)
hsa-miR-31 (2.26) hsa-mir-493 (1.14) hsa-mir-675 (-1.61)
hsa-miR-34a (2.2) hsa-mir-127 (1.12) hsa-mir-9-1 (-1.51)
hsa-miR-181b-2 (2.04) hsa-mir-509-2 (1.11) hsa-mir-9-2 (-1.49)
hsa-miR-205 (1.79) hsa-mir-134 (1.11) hsa-mir-7-2 (-1.25)
hsa-miR-21 (1.78) hsa-mir-199b (1.1) hsa-mir-363 (-1.14)
hsa-miR-509-1 (1.74) hsa-mir-214 (1.07)
hsa-miR-509-3 (1.68) hsa-mir-199a-2 (1.06)
hsa-miR-181a-2 (1.65) hsa-mir-675 (1.06)
hsa-miR-891a (1.65) hsa-mir-199a-1 (1.06)
hsa-miR-509-2 (1.59) hsa-mir-514-1 (1.03)
hsa-miR-508 (1.56) hsa-mir-514-2 (1.029)
hsa-miR-181b-1 (1.52) hsa-mir-337 (1.02)











are shown in bolds
* log2 FC of expression
Table5 Click here to access/download;Table;Table 5.xls
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RNASeq-stage I Clusters miRNASeq-stage I Clusters
Cluster 1 (n=35) Cluster 1 (n=2)
Cluster 2 (n=7) Cluster 2 (n=8)
Cluster 3 (n=102) Cluster 3 (n=135)
Cluster 4 (n=115) Cluster 4 (n=88)
Cluster 5 (n=3) Cluster 5 (n=40)
Table7 Click here to access/download;Table;Table 7.xls
Downs (log2 FC) Cluster (log2 FC) Transitions (log2 FC)
SNX20 (-1.12) 5 stage i-ii (-1.16)
KIF5C (-1.09) 5 stage ii-iii (-1.62)
TRIB3 (-1.71,-1.62) 5 & 6 stage ii-iii (-1.25)
PLA2R1 (-1.41,-1.49) 1 & 2 stage iii-iv (-1.28)
LTF* (-1.64) 3 stage iii-iv (-1.18)
* LTF significant down-regulation (log2 FC = −3) was
observed in 21 out of 102 PTC patients in cluster 3.
Table8 Click here to access/download;Table;Table 8.xls
Ups (log2 FC) Cluster Transitions (log2 FC)
TNFSF13B (1.02) 1 stage ii-iii (1.07)
CST7 (1.41) 1 stage ii-iii (1.39)
SCEL (1.51) 1 stage ii-iii (1.42)
RUNX3 (1.06) 5 stage ii-iii (1.13)
FN1 (1.35) 5 stage ii-iii (1.92)
GNLY (1.21) 5 stage ii-iii (2.07)
IL1RN (1.18) 6 stage ii-iii (1.05)
cluster1-stage I(down)cluster2-stage I(down)cluster3-stage I(down)cluster4-stage I(down)cluster5-stage I(down)cluster6-stage I(down)cluster1-stage I(up)cluster2-stage I(up)cluster3-stage I(up)
SPON2 LIMA1 SLC36A1 ZDHHC1 RNF145 MED7 TTC31 GPR137 ZDHHC2
CHST10 MED17 MOGS SLC24A1 CDK9 TRIB3 CAVIN2 PHLPP1 GEMIN2
DCHS1 NT5C3A GDPD3 MOB4 NME6 KBTBD6 RNF144A PSPC1 WTIP
SOX4 CD9 ARVCF SEMA3B CORO1B SYTL2 REX1BD CDV3 NPHP3
NFYC E2F5 LTF GGPS1 FAM149A EMP1 EMCN FAM241B KLHL29
TGM1 REV3L DDX19B TRIM38 DNAJC7 MTERF3 NCSTN DAAM1
PRPS1 KAT6B COX7B C11orf74 UBE2V2 FAM129A ABT1 LRRIQ3
UBQLN4 CITED2 CDCA7L FERMT3 UBAC2 HTATSF1 DDX19B VPS18
RABL2B TGFBR2 ZNF226 SLC4A3 SLC25A45 STEAP3 DDX11 EHD3
SPCS1 WBP4 CYTH1 CAPZB RPL7P9 CFAP53 IK ZC3H15
OPRL1 ZNF319 VAT1 NFYC COLEC12 RHBDL2 LBHD1 SIN3A
CABLES2 C16orf87 PDGFD LIMA1 PAQR8 CNPPD1 UTP23
DPYSL3 AGAP2 RNF144A STK38 SP4 SMUG1 MRPL27
SEMA3B AGBL2 ZNF701 PER2 ZBTB17 RBM45 DLX3
LIMA1 NANS PTCD2 SCNM1 ARG2 NTRK2 PHACTR1
HS2ST1 HSPB6 NUDT13 HSPA4L MAPK7 GUCY1B1 ERLEC1
MARK1 ABCD3 PRSS16 FRMPD3 INTS4 NDUFAF6 TMEM91
B3GNT7 ZNF141 STYXL1 AIFM1 COQ2 HPRT1 LONRF1
FBXO7 PTGDS MCTP2 TMEM44 SLC26A2 GTF3C4 ZFP37
TM7SF3 BLNK LYSMD1 CRTC1 FAM210B SERINC3 ZNF212
SLC24A1 PDPK1 DLGAP4 NACC1 SAP30L PTCD2 OVGP1
DDIT4 URGCP ACAA2 SMOX DUS4L RMND1 NKIRAS2
CLDN12 HMGCS1 GSE1 RLF MED17 EPHA1 NCSTN
EZH1 IGSF9B FAM50B CCZ1 PUSL1 ZNF280D PTCD2
MRPL49 IDH3A DOK3 PPDPF PAM SMPD1 STARD8
SPRY1 IDH1 CXCL12 KLHL18 PKM LTF VPS8
SPAST SOBP MPHOSPH10NFU1 RPS6KA6 WIPF3 ZDHHC2
PTPRK TFPI SELENOI CDC42EP2 CMAHP TRMT112 MAPK7
TNFAIP8L2 PDK4 SOBP WBP4 SEMA7A PPP1R14B NCOA5
TBC1D19 SEMA4C MRNIP SUSD3 SSBP1 RNF180 ETFB
TMEM128 BCLAF3 RPA3 RTN2 TCAF2 FGL2 CDK8
TBCA YIPF3 PER2 FEZ2 UBLCP1 TRIM21 QSOX1
CRTC1 B3GNT7 STK33 YWHAH PLB1 CYP4B1 SYNJ1
PSME4 TIPRL RARA RPS21 FUZ HMGXB4 EXOC8
ATP6V1A NRM CEP126 CSNK1A1 HID1 INTS10 SMUG1
SPA17 PRPF4 SMS COQ3 PINK1-AS CLCN6 IL23A
NT5C3A TRAF2 CACNA2D2 UBP1 ZNRD1 FAM50B FADD
FBXL2 C1orf54 USP11 PRXL2B ARL5A CENPU DMAC2
FAM83F SAC3D1 TBC1D9 UPF3A POU2F2 PTER
PKIA SPEF2 C9orf40 WBP4 UBXN2A DAB2
HBS1L RHOT1 BTD WDR36 SGCB DBT
POLR2J3 NT5C2 ECD ARHGAP33 MRPL27 ZNF500
DLG2 AXIN2 VAMP4 PCM1 SLC22A17 CDS2
LATS2 MEF2C SFXN1 TTLL7 3-Mar EIF4A2
TBC1D9 SUB1 LMNB2 MDGA1 ZNHIT1 TAF3
RAD23B FZD7 UBASH3B RTEL1-TNFRSF6B TOR2A NUP35
supplementary table 1 Click here to access/download;Table;Supplementary table 1.xls
HECW2 CHST14 CUL7 C1QC BHMT2 DDX27
SECISBP2L RGS1 PRPF4B CEMIP LPIN1 VASN
EPAS1 PTGES2 FBXW7 CCDC90B EDC4 EFHD2
ATRN FBXL15 LPIN1 RPS25 INPP4A BEST1
BUB3 MCRIP2 SAP18 COBLL1 SP4 MIDN
KAT6B DGKE NOLC1 SVOPL SCLY RPS16
MEF2C DHRS3 CIR1 TOM1L1 GSE1 SRP19
MR1 ABHD8 SUMO1 MAP2K5 CACNA2D2 SRP54
VAMP4 2-Sep SH3BP5L RAD51AP1 SNRNP40 WEE1
SLC25A28 LCMT2 MRPL10 GMNN EDA KDELR1
MED17 KLF7 BTRC TAF3 FBXO21 ADIPOR1
ABTB1 KIF7 SRSF12 CTDSPL C1QTNF6 EMC9
TAPT1 ABCB7 CABLES2 LURAP1L TENM4 PSTPIP1
SDF2L1 REV1 MFSD9 VPS13D TMED10 ZNF415
NOMO1 ACTR6 GRAMD2B MFSD1 NDUFS7 UBFD1
PKN1 TMEM144 EIF4A2 ATP13A2 NAT14 BAHD1
CMAHP CCNI RETSAT ATRN RASSF4 UBE2S
LARP6 WDR13 DICER1 ZNF317 STIM2 RTN4
ANKH NOMO1 CCDC47 LSM11 ATP1B1 PEBP4
PIP4K2C ZC3H11A TRMT5 CTDSPL2 IKZF5 TMPO
SRSF2 ACAP2 SLC16A2 C7orf50 RPS9 GBA2
C9orf40 NDUFS2 RABL2B NBEA MEMO1 PMEPA1
AP3S2 RABAC1 TRMT61A ZSWIM6 SMAD5 TRIM65
NUP205 SENP6 TNFRSF14 ACE PCSK4 SSR1
SERINC5 CDS1 B4GALT7 ADAM9 SCEL BTRC
CENPJ STIL C19orf66 POMGNT2 TMEM243 ING1
NT5C2 SH3BGRL3 WDR24 DDX24 DENR PTPMT1
NOSIP PLA2R1 POGK VAPA COL9A3 PHF11
TRAPPC12 SLAIN1 HS2ST1 DNAJC8 GTF2IRD2B CAMK2D
PLXDC2 KRTCAP2 C16orf74 RHOF ALDH1L2 ORMDL1
TRPC1 INHBB KANK1 GALNT12 CDC42EP2 GAS2L3
WBP4 VEGFB EPC1 GGPS1 FBXO30 EPHX4
SMOX ANTXR2 GNAQ NDST2 VPS36 ANKRD49
SUB1 KLHL8 TMEM54 BHLHE41 C3AR1 BEX3
MFF EXO5 CYTH3 FBXO44 HMGA1 OAT
GSTM4 SDF4 TBC1D19 GRB14 SUMF1 NLK
PDE8B HIPK3 EPM2A SNX30 ETFA SH3TC1
ST6GALNAC6 MAPK1IP1L IMMP1L BRWD3 COX7B SEH1L
KLHDC2 IFT22 PEX11B AHSA2P ATP8A1 VPS37C
CYTH3 ZNF281 CTNNAL1 B3GALNT2 RPUSD4 PRTFDC1
PPAN FECH GPX7 TLE3 WIPF1 LEMD2
TMEM42 BNIPL RCN3 RENBP TVP23A NAT10
UBQLN1 VAPA WDR73 EPB41L5 TRA2A SNAPC4
ORC3 AK4 FAM171B YDJC MCC CYP39A1
USF1 ACTR2 C1orf21 PGAP2 E2F6 PPIP5K1
E2F5 LIMK1 KLC4 GABARAPL2TMEM30A
VAPA CTSF STX18 CTSC PQBP1
PPIP5K1 DARS CTSA ERCC2 DEPP1
OPA3 TCFL5 ZER1 PEX10 MOCS1
ZNF835 MYO7B TRIB3 NBPF20 ACOX2
TP53INP2 CTDSPL2 ZNF30 AGK ARL6
MED6 OVOL1 BTNL9 ELF2 BHLHE41
KIF26B FAM192A GRB7 FBXL17 ASNSD1
SPINT1 NPEPPS PITPNM2 CDK19 ADGRG6
NEK6 SNTA1 KIAA0232 MTF2 FAAH
CCDC28A SPC24 SPATA2 SLC7A7 INPP5A
ENOX2 NMNAT2 NAPSA CCNK NPAT
ZNF143 FBXL8 PALD1 CST7 EFNA3
IGFBP3 ZFAT RCOR2 ARCN1 CCAR1
ZFYVE19 CTPS2 C21orf91 SNRPF HNRNPF
SHC3 IFIT2 HSD17B1 PRSS16 SERTAD4
CITED2 RND3 DCTN5 C20orf27 TPST2
SMIM14 LPAR6 SGK3 TTC1 CCDC186
SGSM2 LSS FAM193A NEGR1 BICDL1
TBCEL CRAT FAM50A PARP11 TPP2
CMIP TMEM184A PHOSPHO2 GPR137 NSF
BAX GALNT12 NPNT PDK2 CHORDC1
ALPL VPS29 CDCA5 GDPD3 BCLAF1
ZNF524 MOCOS TMBIM1 ITM2C SPPL3
CTNNBL1 FBXW5 TPD52L1 SUPT7L GDF9
SDF4 TLK2 L3HYPDH MGAT3 BET1
TPPP ATP5F1A TRIM4 MCTP2 MED29
SUN1 ROCK2 PHYHIP TMOD3 TRA2A
SENP6 MAPK9 TRMO CEP19 LSP1P4
ZFYVE27 ASIC1 PCTP TMED2 SERPINF2
IFT22 KIF26B SCAF1 PDGFD PPP1R3F
RASA2 ZNF263 FRS2 MAT2B SYTL1
TIPRL EIF4A1 LAMC2 ACPP FGL2
TMEM140 OPN3 BSDC1 ARL5A PTPRM
XXYLT1 ABHD18 BICRAL NCL C6orf62
C1orf54 TAF6L TPP1 YKT6 BRCA1
VIPR1 WBP2 ERAP2 FGD5 ZNF214
MRPL36 ATF7 MXRA8 APH1B EIF1
ZNF837 PRELID3A CCDC32 RAB5A PPP1R35
RPS3 DCAF16 ZNF506 SHCBP1 TMED1
CMPK1 ZNF227 RPS6KA5 CEP126 SYNE1
FRS2 PCSK5 CSNK1A1 FBXL5 OGFOD2
REV1 AGPAT4 YWHAQ TSPAN2 SLC30A7
BCL3 AK8 CCND1 SNX27 OCIAD2
ZMAT5 ETV3 KLHL15 MYCL ARGLU1
FAM83B PPOX HSPA8 DTX4 SCAF1
TM4SF1 FBXO45 CEP83 ADGRL2 POLI
GPX8 AP1S3 REEP6 FAAP24 C17orf80
TMX1 MEIS1 AHR WDR7 TUBA4A
DTWD2 EPHB2 ANGPT2 RPL29 NCF4
SLC46A1 JAGN1 ORMDL3 RHOQ PWWP2A
IFI27 NQO2 KIF1B ELL FKBP8
NDUFB10 FCGR2A NEK6 RFC4 THEMIS2
RPRD1B SLIRP PSMA7 CCAR1 RAB40B
CAB39L ANGPT1 MRGPRF ZSWIM3 TNFRSF14
PRKACA DNM2 CREM LPGAT1 CLDN16
ACAD8 MAML1 MAPKBP1 FAM8A1 ANO7
CUL3 DCP2 NFIL3 TUBGCP6 TYW3
EPB41L4A C11orf58 PCOLCE TMC6 SCNM1
COLGALT1 WDR18 SULF1 PTP4A1 KCNC3
RANBP2 ACAA1 SLC7A1 SENP7 KNOP1
RTEL1-TNFRSF6BSTAU1 ZMYND10 P3H2 PSMA2
CCRL2 FAM171B SLC35E4 SMS TFCP2L1
HSPB6 FAM86FP YIPF1 ATP10D PATJ
HMGCS1 METTL7B TRPT1 ARHGAP25 RTN3
FAM241B GBGT1 ZNF382 ADAMTS1 FOLR2
TENM1 CWC15 L3MBTL2 CPNE8 BTN2A3P
CACNA2D1 MCC CNTN4 SH2B2 RCAN1
OXR1 BAK1 LDLRAP1 COX18 PRPF6
CXCR4 PSMG3 PIGG LACTB AASS
EIF4A2 PPP2R5C TAF6L HNRNPH3 RNF4
ALG1 IL15 RTF1 PLEKHA2 COQ3
RPN2 HNRNPU CDK5RAP2 CTDSP1 GATAD1
STK17A SEC24B STAT2 SLC45A3 TRO
ZDHHC2 NLRP1 CPSF6 PITHD1 LZTR1
ZNF526 RTN4IP1 NFKBIA YWHAG
ARHGEF1 AAAS ZNF582 PIGR
PSD3 BAX LUC7L TMEM241
HSPB2 AGA ZNF597 YPEL3
IRF6 COA7 ANAPC11 TM6SF1
MOSPD1 RIOK1 PIGC IQCE
MCRIP2 POLR2J3 SLC14A1 ALMS1
SMURF2 PPWD1 TBC1D30 FUOM
CPXM2 ZBED3 ZNHIT2 SCAMP2
PTPN13 GNAO1 UBIAD1 GATAD2A
ADGRG6 PAK1 NRM CLPB
DIRC2 RAPGEF4 ANGEL1 SAV1
PINK1-AS PTEN SERF2 RANBP9
FMO4 CPSF3 HPS6 ZER1




















































































































































































































































































































































































































































































































































Figure 1: Overall work flow of the study. 
Figure 2: Down-regulated genes in PTC (blue) involved in signaling pathways (pink). 
Figure 3: Up-regulated genes in PTC (blue) involved in signaling pathways (green). 
Figure 4: Pathways (light blue) associated with deregulated genes (orange) with the altered 
pattern of expression in stage I to II and stage II to III progressions. 
Figure 5:  Clustering of stage I patients using GeneE program. 
 
Figure legends Click here to access/download;Supplementary Material;Figure
legends.docx
Table 1: Number of samples in stage I-IV as well as normal thyroid tissue samples. 
Table 2: Clinical information of samples (Stage I-V). 
Table 3: Up-regulated genes and corresponding log2FCs in sequential PTC stage progression. 
Table 4: Down-regulated genes and corresponding log2FCs in sequential PTC stage progressions. 
Table 5: Deregulated miRNAs and corresponding log2FCs in sequential PTC stage progressions. 
Table 6:  Lists of DEGs with the opposite pattern of expression between different PTC stages. 
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